A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kevin Kalinsky, Prabhjot Singh Mundi, Codruta Chiuzan, Melissa Kate Accordino, Meghna S. Trivedi, Joseph A. Sparano, Sun Young Oh, Amy Tiersten, Ruth O'Regan, Francisco J. Esteva, Sarika Jain, Ingrid A. Mayer, Andres Forero, Lea N. Baer, Katherine D. Crew, Dawn L. Hershman, Christos Vaklavas
Institutions: Columbia University Irving Medical Center, Montefiore Medical Center, Mount Sinai Hospital, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, New York University, Northwestern University, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of Alabama at Birmingham, Stony Brook University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2624550665